Cargando…

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

BACKGROUND: GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initially necessitating short in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nauck, Michael A., Quast, Daniel R., Wefers, Jakob, Meier, Juris J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085572/ https://www.ncbi.nlm.nih.gov/pubmed/33068776 http://dx.doi.org/10.1016/j.molmet.2020.101102

Ejemplares similares

Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD
por: Østergaard, Jakob A., et al.
Publicado: (2022)

GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art
por: Granata, Antonio, et al.
Publicado: (2022)

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
por: Mentis, Nikolaos, et al.
Publicado: (2011)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
por: Nauck, Michael A., et al.
Publicado: (2022)

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
por: Boye, Kristina S., et al.
Publicado: (2019)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective
por: Laspe, Insa, et al.
Publicado: (2023)

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2021)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
por: del Olmo-Garcia, María Isabel, et al.
Publicado: (2018)

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
por: Urva, Shweta, et al.
Publicado: (2020)

Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment
por: Brooks, Anne, et al.
Publicado: (2019)

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
por: Meier, Juris J., et al.
Publicado: (2010)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chia, Chee W, et al.
Publicado: (2009)

Effects of GLP-1 receptor agonists on neurological complications of diabetes
por: García-Casares, Natalia, et al.
Publicado: (2023)

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
por: Gallwitz, Baptist
Publicado: (2015)

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
por: Trujillo, Jennifer
Publicado: (2020)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
por: Sohn, Minji, et al.
Publicado: (2023)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
por: Imai, Kenjiro, et al.
Publicado: (2014)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
por: Antza, Christina, et al.
Publicado: (2019)

GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
por: Rasalam, Roy, et al.
Publicado: (2019)

Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes
por: Gavigan, Colleen, et al.
Publicado: (2023)

Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review
por: Birker, Sebastian, et al.
Publicado: (2022)

Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
por: Al-Sadawi, Mohammed A., et al.
Publicado: (2023)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
por: Stolar, Mark W, et al.
Publicado: (2013)

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
por: Moreira, Rodrigo Oliveira, et al.
Publicado: (2018)

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
por: Kaneko, Shizuka
Publicado: (2022)

Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists
por: Umapathysivam, Mahesh M, et al.
Publicado: (2023)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata
por: Goggins, Michael
Publicado: (2012)

Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Goldman, Jennifer D.
Publicado: (2020)

Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes
por: Ehsasatvatan, Maryam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e9jfvkatg23i50k8o02hlptgji